Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 28

1.

Safety, immunogenicity, and tolerability of meningococcal serogroup B bivalent recombinant lipoprotein 2086 vaccine in healthy adolescents: a randomised, single-blind, placebo-controlled, phase 2 trial.

Richmond PC, Marshall HS, Nissen MD, Jiang Q, Jansen KU, Garcés-Sánchez M, Martinón-Torres F, Beeslaar J, Szenborn L, Wysocki J, Eiden J, Harris SL, Jones TR, Perez JL; 2001 Study Investigators.

Lancet Infect Dis. 2012 Aug;12(8):597-607. Epub 2012 May 7.

PMID:
22569484
2.

Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.

Carter NJ.

BioDrugs. 2013 Jun;27(3):263-74. doi: 10.1007/s40259-013-0029-2. Review.

PMID:
23575646
3.

Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).

Gandhi A, Balmer P, York LJ.

Postgrad Med. 2016 Aug;128(6):548-56. doi: 10.1080/00325481.2016.1203238. Epub 2016 Jul 7. Review.

PMID:
27467048
4.

Meningococcal serogroup B vaccines: Estimating breadth of coverage.

Donald RG, Hawkins JC, Hao L, Liberator P, Jones TR, Harris SL, Perez JL, Eiden JJ, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2017 Feb;13(2):255-265. doi: 10.1080/21645515.2017.1264750. Epub 2016 Dec 14. Review.

5.

A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?

Martin NG, Snape MD.

Expert Rev Vaccines. 2013 Aug;12(8):837-58. doi: 10.1586/14760584.2013.814862. Review.

PMID:
23984957
6.
7.

The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.

Zlotnick GW, Jones TR, Liberator P, Hao L, Harris S, McNeil LK, Zhu D, Perez J, Eiden J, Jansen KU, Anderson AS.

Hum Vaccin Immunother. 2015;11(1):5-13. doi: 10.4161/hv.34293. Epub 2014 Nov 1. Review.

8.

Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.

Esposito S, Principi N.

Expert Rev Vaccines. 2014 Feb;13(2):193-202. doi: 10.1586/14760584.2014.874949. Epub 2014 Jan 6. Review.

PMID:
24393061
9.

Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.

Dull PM, McIntosh ED.

Vaccine. 2012 May 30;30 Suppl 2:B18-25. doi: 10.1016/j.vaccine.2012.01.062. Review.

PMID:
22607895
10.

A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease.

Su EL, Snape MD.

Expert Rev Vaccines. 2011 May;10(5):575-88. doi: 10.1586/erv.11.32. Review.

PMID:
21604979
11.

Prevention of rare diseases: how revolutionary techniques can help vulnerable individuals-the example of serogroup B meningococcal infection.

McIntosh ED, Carey V, Toneatto D, Dull P, Wassil J.

Ther Adv Vaccines. 2015 Jan;3(1):13-23. doi: 10.1177/2051013614557477. Review.

12.

Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults.

Nolan T, O'Ryan M, Wassil J, Abitbol V, Dull P.

Vaccine. 2015 Aug 26;33(36):4437-45. doi: 10.1016/j.vaccine.2015.06.011. Epub 2015 Jul 15. Review.

13.

The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.

Mameli C, Galli E, Mantegazza C, Fabiano V, Zuccotti GV.

Future Microbiol. 2015;10(10):1579-98. doi: 10.2217/fmb.15.91. Epub 2015 Oct 6. Review.

PMID:
26437903
14.

Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.

Esposito S, Castellazzi L, Bosco A, Musio A, Stoddard J.

Immunotherapy. 2014;6(4):395-408. doi: 10.2217/imt.14.11. Review.

PMID:
24815780
15.

A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty.

Andrews SM, Pollard AJ.

Lancet Infect Dis. 2014 May;14(5):426-34. doi: 10.1016/S1473-3099(13)70341-4. Epub 2014 Mar 25. Review.

PMID:
24679664
16.

Outbreaks of meningococcal B infection and the 4CMenB vaccine: historical and future perspectives.

Whelan J, Bambini S, Biolchi A, Brunelli B, Robert-Du Ry van Beest Holle M.

Expert Rev Vaccines. 2015 May;14(5):713-36. doi: 10.1586/14760584.2015.1004317. Epub 2015 Jan 21. Review.

PMID:
25603916
17.

Meningococcal Antigen Typing System Development and Application to the Evaluation of Effectiveness of Meningococcal B Vaccine and Possible Use for Other Purposes.

Domnich A, Gasparini R, Amicizia D, Boccadifuoco G, Giuliani MM, Panatto D.

J Immunol Res. 2015;2015:353461. doi: 10.1155/2015/353461. Epub 2015 Aug 17. Review.

18.

Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older.

COMMITTEE ON INFECTIOUS DISEASES.

Pediatrics. 2016 Sep;138(3). pii: e20161890. doi: 10.1542/peds.2016-1890. Review.

19.

Group B meningococcal vaccine science and policy.

Drysdale SB, Pollard AJ.

J Infect. 2015 Jun;71 Suppl 1:S15-20. doi: 10.1016/j.jinf.2015.04.021. Epub 2015 Apr 24. Review.

PMID:
25917798
20.

A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program.

O'Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM.

Drugs. 2014 Jan;74(1):15-30. doi: 10.1007/s40265-013-0155-7. Review.

Supplemental Content

Support Center